Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alza's Doxil and Ethyol

Executive Summary

The Oncologic Drugs Advisory Committee will meet June 8 to discuss Doxil (liposomal doxorubicin) for the treatment of metastatic carcinoma of the ovaries in patients refractory to both paclitaxel and platinum-based chemotherapy and who may also be refractory to topotecan. The committee will meet in the afternoon of June 8 to review Alza/U.S. Bioscience's Ethyol (amifostine) for the reduction in incidence and severity of radiation-induced xerostomia. The meeting will begin at 8:00 a.m. at Town Center Hotel in Silver Spring, Md
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS034076

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel